[Hemostasis tests as markers of hepatic and endothelial toxicity in chemotherapy].
Two short-lived vitamin K-dependent factors, factor VII and protein C, were measured by both functional and antigenic techniques in 3 hematological conditions known for their risk of hepatotoxicity: Following use of asparaginase and bisantrene, and patients at high risk of hepatic veno-occlusive disease after allogenic bone marrow transplantation for relapse of acute leukemia of accelerated phase of evoluted chronic myelogenic leukemia. In these 3 conditions functionally measured levels of protein C and factor VII, and antigenically measured levels of both these factors proved to be early markers of incipient hepatic involvement. These tests were easy to use routinely were reproducible, and proved to be predictive of veno-occlusive disease in grafted patients at the preconditioning stage. In the follow-up of bone marrow grafted patients plasma markers of endothelial function (von Willebrand's factor, tissue type plasminogen activator, and plasma activity of angiotensin converting enzyme) were significantly altered at the time of overdose with cyclosporin A, probably due to a drug-induced in vivo lesion of the endothelium. In the search for cytoprotective drugs for the prevention of veno-occlusive disease in bone marrow grafted patients prostaglandin E1 (PGE1) was given prior to and for at least 4 weeks after transplantation and proved to be effective by biological criteria (the level of protein C mainly). This deserves further study in a prospective clinical trial of the potential usefulness of PGE1 in preventing liver veno-occlusive disease in bone marrow grafted patients.
Scrobohaci
M L
ML
Département d'Hémostase, Hôpital Saint-Louis, Paris, France.
Drouet
L
L
Baudin
B
B
D000527:Alprostadil / Q000627:therapeutic use; D000873:Anthracenes / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001215:Asparaginase / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003524:Cyclosporins / Q000627:therapeutic use; D004730:Endothelium, Vascular / Q000187:drug effects*; D005167:Factor VII / Q000032:analysis; D006489:Hemostatic Techniques; D006801:Humans; D008099:Liver / Q000187:drug effects*; D011486:Protein C / Q000032:analysis
D000873:Anthracenes; D000970:Antineoplastic Agents; D003524:Cyclosporins; D011486:Protein C; C031404:bisantrene; D005167:Factor VII; D001215:Asparaginase; D000527:Alprostadil
Les tests d'hémostase, marqueurs de la toxicité hépatique et endothéliale des chimiothérapies.